(Reuters) - Botox-maker Allergan Plc (AGN.N) reported a better-than-expected quarterly profit, helped by strength in its medical aesthetics unit, prompting the drugmaker to raise its full-year revenue forecast.
The company said it now expects full-year revenue in the range of $15.85 billion to $16.05 billion from its previous forecast of $15.80 billion to $16 billion.
Net revenue for the quarter rose 9 percent to $4.01 billion, beating Wall Street estimates of $3.94 billion.
Revenue in its medical aesthetics unit, which includes its Botox blockbuster wrinkle treatment, rose more than 53 percent to $643.9 million.
Excluding special items, the company earned $4.02 per share, topping analysts’ average estimate of $3.92, according to Thomson Reuters I/B/E/S.
Net loss attributable to ordinary shareholders widened to $795.5 million, or $2.37 per share, in the second quarter ended June 30, from $571.3 million, or $1.44 per share, a year earlier.
Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Supriya Kurane